{
  "docId": "019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "docSlug": "2296286e07283457e97b21dc9ce59469",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 46 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 46,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "Includes detailed source citations in the footer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0/7",
  "deckHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0",
  "deckJsonHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0.json",
  "deckAnchorHref": "/decks/019de075-a5cb-73ea-a4ef-8f4a27a8a7b0#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.08,
        "y": 0.23
      },
      "kind": "chart",
      "text": "Overall Response Rate in relapsed/refractory AL Amyloidosis",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26e4df9a-09a7-4d6a-9906-5375d583d669",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.72,
        "y": 0.2
      },
      "kind": "list",
      "text": "NXC-201 Only CAR-T in AL Amyloidosis; NXC-201 100% Overall Response Rate; Organ responses exceed purpose-designed CAEL-101 and Birtamimab combinations; Zero Neurotoxicity of any grade",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b218fc29-cd07-4608-b38c-2bd3cd2175d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Birtamimab Source: Gertz MA et al... CAEL-101... Darzalex source... The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in 2025, according to Grand View Research.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e2e4a29-92ff-4183-bb2d-6be401a3864d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in relapsed/refractory AL (light chain) Amyloidosis, a $6 billion market by 2025",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eceb8847-1431-47c1-a672-994ddb57d75c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "5027be93-535f-449a-9c55-44f893156c27",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The presentation highlights the limitations of current treatments.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5f2e0111-b5c3-4127-8874-dd9c86260d92",
      "evidence": "The presentation highlights the market opportunity and the limitations of current treatments.",
      "position": 0,
      "objective": "What are the consequences of not addressing the unmet medical needs?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}